Skip to content
thestock.space

Tyche Industries (BSE: TYCHE) had a P/E of 24.2× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 30% below their 52-week high. Sales and net profit fell 11% and 21% a year over 3 years; its ROCE of 6.7% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, though net profit is above operating profit, which points to a one-off gain. Its dividend yield is 3.4%. It is a small-cap company with a market cap of ₹106 Cr, ranked 118th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 22% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹106.00
Day high
₹108.75
Day low
₹101.62
Prev. close
₹105.07
Volume
2.2K

Health check

1 fair · 4 to check
  • ReturnsBehind

    −21.6% over a year, better than 0 of 7 peers.

  • Price tagDistorted

    A one-off gain inflates profit, so P/E isn’t comparable right now.

  • GrowthShrinking

    Sales −10.7%, profit −21.2% a year over 3 years.

  • ProfitabilityWeak

    ROCE 6.7% vs peer median 17.9%.

  • Balance sheetFair

    Piotroski 4 of 9.

  • Red flags5 to check

    Return on equity is low at 5.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹106 Cr, #118 of 154 in its industry by size.

Defensive

Beta 0.56 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹50 Cr · profit ₹4 Cr
Market cap
₹106 Cr
Small cap
P/E
24.2
Industry 28.7
Price to book
0.81
Peers 4.99
Dividend yield
3.38%
ROE
5.0%
Peers 14.7%
ROCE
6.7%
Peers 17.9%
Debt to equity
n/a
Debt ₹0.00 Cr
EPS (TTM)
₹4.28
OPM (TTM)
−2.8%
Net margin 8.9%
Sales growth
−28.4%
Latest quarter vs a year ago
Profit growth
−101.7%
Latest quarter vs a year ago
Price to sales
2.12
EV/EBITDA −20.9

Strengths and risks

Strengths

  • Dividend yield of 3.38%.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 5.0%.
  • Quarterly profit down 101.7% on a year ago.
  • Quarterly sales down 28.4% on a year ago.
  • Net profit is above operating profit, so a one-off gain is likely flattering earnings.
  • 30% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Tyche Industries

Tyche Industries Limited manufactures and sells active pharmaceutical ingredients and intermediates in India. The company also provides chiral intermediates and nutraceuticals ingredients; and contract drug substance and analytical development, as well as contract development and manufacturing organization services. It primarily exports its products to the United States, Europe, and internationally. Tyche Industries Limited was incorporated in 1998 and is…

Headquarters
Hyderabad
Employees
167
Sector
Healthcare
ISIN
INE443B01012
Website
tycheindustries.net

Price range

52 weeks

₹98.00₹148.00

Today

₹101.62₹108.75
Avg volume (3M)
6.6K
1-year return
minus 21.6%
From 52-week high
minus 30.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
TYCHETyche Industries103.54minus 1.46%10624.20.816.7%5.0%−2.8%−10.7%−21.2%3.38%minus 21.6%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
12.714.210.616.29.1
10.814.39.516.910.8
1.9−0.11.1−0.7−1.7
15.3%−0.9%10.3%−4.1%−18.6%
1.82.61.932.3
0––0–
0.50.50.50.60.6
3.322.51.7−0.1
25.4%25.7%25.9%32.0%22.6%
2.41.51.81.2−0
2.371.491.781.05-0.04

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−10.7%
Profit CAGR 3Y
−21.2%
EPS CAGR 3Y
−21.2%
ROE
5.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
75.469.565.553.6
–minus 7.8%minus 5.8%minus 18.1%
5956.753.550.9
16.412.8122.8
21.7%18.4%18.4%5.2%
4.65.76.78.5
1.81.922
−0.1000.2
19.116.616.79.5
25.7%26.4%25.8%26.7%
14.212.212.46.9
–minus 13.6%+1.3%minus 44.1%
13.8311.7812.116.77

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.210.210.210.2
107116126130
207.910.77.6
137135147148
16.617.916.618.9
––0.2–
5.12.98.920.1
69.375.881.271.9
45.838.140.537.1
137135147148

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6.47.78.52.9
−3.13.9−0.6−8.9
−1.5−2−2.6−3.1
1.89.65.4−9.2
−1.8−3.2−0.7−4.3
4.74.57.8−1.4
−1.5−2−2.6−3.1

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you